OCGN: Kapitalisasi marang pendapatan Ocugen Pharma

The market capitalization-to-revenue ratio illustrates the asset's dynamics, where the 58.90 mark captures this metric. Ocugen, Inc. (OCGN) is developing gene therapy while awaiting FDA approval for its OCU400 drug. The company's environmental policy is based on laboratory emission filtration and energy efficiency. The current development vector relies on compliance with basic waste disposal norms and sustainable development standards.

The P/S multiple determines the market value of a business relative to its annual revenue, allowing for an assessment of the premium paid per unit of generated revenue within fundamental analysis. The P/S ratio dynamics reflect the dependence of Ocugen, Inc. (OCGN) capitalization on regulatory expectations, where the gap between price and actual sales highlights high financing risks in the absence of guaranteed commercial demand for its drugs.